Evidence map›Paper›PMID 31207561›Full record

ArticleJournal of affective disorders2019

Health-related quality of life in remitted psychotic depression

Kathleen S Bingham, Ellen M Whyte, Benoit H Mulsant, Anthony J Rothschild, Matthew V Rudorfer, Patricia Marino, Samprit Banerjee, Meryl A Butters, George S Alexopoulos, Barnett S Meyers and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of affective disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Kathleen S BinghamUniversity of Toronto, Department of Psychiatry, Toronto, ON, Canada. Electronic address: kathleen.bingham@uhn.ca.
Ellen M WhyteUniversity of Pittsburgh School of Medicine, Department of Psychiatry, Pittsburgh, PA, United States.
Benoit H MulsantUniversity of Toronto, Department of Psychiatry, Toronto, ON, Canada; Centre for Addiction and Mental Health, Toronto, ON, Canada.
Anthony J RothschildUniversity of Massachusetts Medical School, Department of Psychiatry, Worcester, MA, United States.
Matthew V RudorferNational Institute of Mental Health, Rockville, MD, United States.
Patricia MarinoWeill Cornell Medical College, Department of Psychiatry, New York, NY, United States.
Samprit BanerjeeWeill Cornell Medical College, Department of Biostatistics and Epidemiology, New York, NY, United States.
Meryl A ButtersUniversity of Pittsburgh School of Medicine, Department of Psychiatry, Pittsburgh, PA, United States.
George S AlexopoulosWeill Cornell Medicine, New York-Presbyterian/Westchester Division, White Plains, NY, United States.
Barnett S MeyersWeill Cornell Medicine, New York-Presbyterian/Westchester Division, White Plains, NY, United States.
Alastair J FlintUniversity of Toronto, Department of Psychiatry, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada.
STOP-PD Study Group
Cornell University · USUniversity of Pittsburgh · USCentre for Addiction and Mental Health · CANational Institute of Mental Health · USPresbyterian Hospital · USUniversity Health Network · CAUniversity of Massachusetts Chan Medical School · USUniversity of Toronto · CA

Funding

Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
Acute Pharmacotherapy of Psychotic DepressionU01MH062518 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI ALEXOPOULOS, GEORGE S · 2002 to 2015
$5.0M
Acute Pharmacotherapy of Unipolar Psychotic DepressionU01MH062565 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WHYTE, ELLEN M · 2002 to 2015
$3.0M
Acute Pharmacotherapy of Unipolar Psychotic DepressionU01MH062624 · NIMH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ROTHSCHILD, ANTHONY J · 2002 to 2015
$2.9M
Acute Pharmacotherapy of Unipolar Psychotic DepressionU01MH062446 · NIMH · UNIVERSITY HEALTH NETWORK · PI FLINT, ALASTAIR J. · 2002 to 2015
$2.0M
NCATS NIH HHS UL1 TR002384NIMH NIH HHS U01 MH062446NIMH NIH HHS U01 MH062518NIMH NIH HHS U01 MH062565NIMH NIH HHS U01 MH062624
6 · The paper itself

Abstract

backgroundSome patients with major depression continue to demonstrate deficits in health-related quality of life (HRQL) following remission. No data exist, however, regarding HRQL in remitted psychotic depression. In this study, we aimed to characterize HRQL in patients with psychotic depression receiving controlled pharmacotherapy.

methodsThis is a secondary analysis of a randomized controlled trial studying continuation pharmacotherapy of psychotic depression. We compared participants' HRQL (measured using the SF-36) between baseline and remission and to population norms. We also compared SF-36 scores stratified by age and gender and examined the correlation between SF-36 scores and medical burden, depression score and neuropsychological performance in remission.

resultsSF-36 scores were significantly lower than population norms at baseline, but improved following remission to the level of population norms. Neither SF-36 scores nor magnitude of SF-36 improvement differed substantially between genders or between younger and older participants. In remission, depression scores were correlated with most SF-36 scales and medical burden was correlated with SF-36 scales measuring physical symptoms. Neuropsychological measures were generally not correlated with SF-36 scores. LIMITATIONS: This study was a secondary analysis not powered specifically to measure HRQL as an outcome variable and the SF-36 was the only HRQL measure used.

conclusionsParticipants with remitted psychotic depression demonstrated levels of HRQL comparable to population norms, despite marked impairment in HRQL when acutely ill. This finding suggests that, when treated in a rigorous manner, many patients with this severe illness improve significantly from a clinical and HRQL perspective.

Indexed as

Cost of IllnessAge FactorsFemaleHumansMajor Depressive DisorderMaleMiddle AgedNeuropsychological TestsQuality of LifeRandomized Controlled Trials as TopicRemission InductionSex Factors

Identifiers

PMID31207561
PMCPMC6822164
OpenAlexW2946927355

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.